

Supplemental Information

Supplemental Methods

Phenotype definitions in HUNT2 dataset

HUNT2 hospital registry and cause of death data was linked to the genotype data. The cause of death registry data was collected at the end of November 2017 and the hospital registry data at the end of December 2017. The end of the follow-up was therefore set at the end of November 2017. Using these two registries, the CAD endpoint was defined as the first occurrence of any of the following ICD-codes in either of hospital or death registry: myocardial infarction or acute ischemic heart disease (ICD10: I21-I24; ICD9: 410), or chronic ischemic heart disease (ICD-10: I25 excluding I25.3, I25; ICD9: 411, 412, 414.0, 414.8, 414.9). This definition of CAD follows the definition of intermediate CAD by Nikpay et al.(25) with the exception of not having the procedure codes available. At baseline, blood pressure medication was collected by self-report, and prevalent diabetes was defined by a combination of self-report and hospital registry data (ICD10: E10-E11 excluding E11.5, E13-E13.9 excluding E13.3, E14.9; ICD9: 250-250.99).

Phenotype definitions in UK Biobank dataset

Incident CAD defined as for intermediate CAD in CARDIoGRAMplusC4D (25). Follow-up is determined as time to first event from baseline, truncating follow-up at 1st February 2020 to avoid confounding from COVID-19 pandemic (either due to SARS-CoV2 exposure or behavioural changes/changes to environment due to lockdown).

- ICD-10: I21-I24, I25.1, I25.2, I25.5-I25.9
- OPSC-4: K40-K46, K49, K50.1, K50.2, K50.4, K75

Prevalent CAD definitions include the above, and additionally:

- ICD-9: 410-412, 414.0, 414.8, 414.9

- (All events with ICD-9 coding are retrospective in UKBB)
- Self-reported heart attack/myocardial infarction at verbal interview (UKBB field #20002, code 1075)
- Self-reported coronary angioplasty (ptca) +/- stent, coronary artery bypass grafts (cabg), or triple heart bypass at verbal interview (UKBB field #20004, codes 1070, 1095, and 1523)
- Self-reported heart attack at touchscreen interview (UKBB field #6150)

Note different nations (England/Wales/Scotland) have different maximum follow-up dates. While hospital records in England and Scotland go beyond 1st Feb 2020, hospital records in Wales are currently only available up until 6th March 2018. In the whole of UKBB (no sample criteria applied), 4.1% of participants have maximum follow-up in the Welsh hospital system. Scotland also has a higher median follow-up time, as on average baseline assessment happened earlier in Scotland than in England or Wales.

Supplemental Tables

Supplemental Table 1. Cohort descriptives of HUNT2 dataset. Baseline characteristics of HUNT2

Variable (units)	Males (N=23,481)	Females (N=27,555)	Incident case males (N=1,846)	Incident case females (N=1,128)	Non-case males (N=21,635)	Non-case females (N=26,427)
	Mean (SD) / N (Proportion)	Mean (SD) / N (Proportion)	Mean (SD) / N (Proportion)	Mean (SD) / N (Proportion)	Mean (SD) / N (Proportion)	Mean (SD) / N (Proportion)
Age (years)	48.7 (16.1)	49.0 (16.5)	65.3 (12.0)	69.2 (11.5)	47.3 (15.6)	48.1 (16.1)
Total cholesterol (mmol/l)	5.77 (1.13)	5.89 (1.31)	6.37 (1.11)	6.89 (1.26)	5.71 (1.12)	5.85 (1.29)
HDL cholesterol (mmol/l)	1.26 (0.33)	1.51 (0.38)	1.20 (0.33)	1.42 (0.39)	1.26 (0.33)	1.51 (0.38)
Systolic Blood pressure (mm Hg)	139.34 (18.55)	134.56 (22.84)	150.89 (22.61)	157.62 (25.17)	138.36 (17.82)	133.58 (22.20)
Currently Smoking (yes/no)	6754 (28.8%)	8278 (30.0%)	653 (35.4%)	327 (29.0%)	6101 (28.2%)	7951 (30.1%)
Blood Pressure medication (yes/no)	2459 (10.5%)	3622 (13.1%)	513 (27.8%)	472 (41.8%)	1946 (9.0%)	3150 (11.9%)
Prevalent Diabetes (yes/no)	659 (2.8%)	719 (2.6%)	171 (9.3%)	133 (11.8%)	488 (2.3%)	586 (2.2%)

N=Number of samples, SD=standard deviation

Supplemental Table 2. Cohort descriptives of UK Biobank dataset. Baseline characteristics of the UK Biobank

Variable (units)	Males (N= 157,570)	Females (N= 214,840)	Incident case males (N= 11,093)	Incident case females (N= 6,476)	Non-case males (N= 146,477)	Non-case females (N= 208,364)
	Mean (SD) / N (Proportion)	Mean (SD) / N (Proportion)	Mean (SD) / N (Proportion)	Mean (SD) / N (Proportion)	Mean (SD) / N (Proportion)	Mean (SD) / N (Proportion)
Age (years)	56.1 (8.15)	56.3 (7.93)	60.0 (6.98)	61.0 (6.59)	55.8 (8.16)	56.2 (7.93)
Total cholesterol (mmol/l)	5.77 (1.02)	6.02 (1.08)	5.93 (1.08)	6.33 (1.14)	5.76 (1.01)	6.01 (1.08)
HDL cholesterol (mmol/l)	1.31 (0.31)	1.62 (0.38)	1.26 (0.31)	1.53 (0.37)	1.31 (0.31)	1.62 (0.37)
Systolic Blood pressure (mm Hg)	140.42 (17.34)	134.33 (19.13)	145.79 (18.28)	142.45 (19.87)	140.01 (17.20)	134.07 (19.05)
Currently Smoking (yes/no)	19,301 (12.3%)	18,712 (8.71%)	1,810 (16.3%)	949 (14.7%)	17,491 (11.9%)	17,763 (8.53%)
Blood Pressure medication (yes/no)	20,013 (12.7%)	24,593 (11.4%)	2,471 (22.3%)	1,627 (25.1%)	17,542 (12.0%)	22,966 (11.0%)
Prevalent Diabetes (yes/no)	2,769 (1.76%)	1,760 (0.82%)	430 (3.89%)	179 (2.77%)	2,339 (1.60%)	1,581 (0.76%)

N=Number of samples, SD=standard deviation

Supplemental Table 3. Summary of the used Cox Proportional Hazards models

Model name	Variables in the linear predictor	Applied dataset
PGSCAD additive model (model C1)	Age+Age ² +Sex+PGSCAD	Combined
PGSCAD with all interactions (model C2)	Age+Age ² +Sex+PGSCAD+Sex*PGSCAD+Age*PGSCAD+Sex*Age +Sex*Age*PGSCAD	Combined
Additive PGSCAD with ASCVD (model C3)	Age+Age ² +Sex+PGSCAD+ASCVD	Combined
PGSCAD with all interactions and ASCVD (model C4)	Age+Age ² +Sex+PGSCAD+Sex*PGSCAD+Age*PGSCAD+Sex*Age +Sex*Age*PGSCAD +ASCVD	Combined
Additive PGSCAD model (model S1)	Age+Age ² +PGSCAD	Sex stratified
PGSCAD with age-interaction (model S2)	Age+Age ² +PGSCAD+Age*PGSCAD	Sex stratified
PGSCAD with age-interaction and ASCVD (model S3)	Age+Age ² +PGSCAD+Age*PGSCAD+ASCVD	Sex stratified

ASCVD=Atherosclerotic cardiovascular disease risk score,
PGSCAD=Coronary artery disease polygenic score

Supplemental Table 4A-E. Baseline linear regression models in HUNT2 dataset

A. $\text{PGSCAD} \sim \text{Sex}$			
Variable	Beta	SE	P-value
Intercept	0.015	0.006	0.013
Sex (0=female, 1=male)	-0.056	0.009	3.0e-10
B. $\text{PGSCAD} \sim \text{Age}$			
Intercept	0.136	0.014	<2.22e-16
Age (year)	-0.003	2.7e-4	<2.22e-16
C. Males only $\text{PGSCAD} \sim \text{Age}$			
Intercept	0.114	0.021	4.2e-8e-9
Age (year)	-3.2e-3	4.0e-4	4.4e-15
D. Females only $\text{PGSCAD} \sim \text{Age}$			
Intercept	0.137	0.019	3.4e-13
Age (year)	-2.5e-3	3.6e-4	7.8e-12
E. $\text{PGSCAD} \sim \text{Sex} + \text{Age} + \text{Sex} * \text{Age}$			
Intercept	0.137	0.019	3.4e-13
Age (year)	-2.5e-3	3.6e-4	7.9e-12
Sex (0=female, 1=male)	-0.023	0.028	0.408
Sex*Age (year for males compared to females)	-6.8e-4	5.4e-4	0.210

PGSCAD =Coronary artery disease polygenic score

Supplemental Table 5. Replication of the baseline PGS_{CAD} trends in UKBB.

A. PGS_{CAD}~Sex			
Variable	Beta	SE	P-value
Intercept	0.052	0.006	2e-20
Sex (0=female,1=male)	-0.034	0.003	3e-24
B. PGS_{CAD}~Age			
Intercept	0.27	0.013	5e-103
Age (year)	-0.004	0.000	8e-94
C. Males only PGS_{CAD}~Age			
Intercept	0.35	0.019	8e-76
Age (year)	-0.006	0.000	2e-72
D. Females only PGS_{CAD}~Age			
Intercept	0.21	0.017	1e-36
Age (year)	-0.003	0.000	1e-31
E. PGS_{CAD}~Sex+Age+Sex*Age			
Intercept	0.23	0.016	6e-46
Age (year)	-0.003	0.000	6e-32
Sex (0=female, 1=male)	0.097	0.023	3e-5
Sex*Age (year for males compared to females)	-0.002	0.000	1e-8

PGS_{CAD}=Coronary artery disease polygenic score

Supplemental Table 6A-B. Baseline linear regression models with all variables in HUNT2 (A) and UKBB (B) datasets with prevalent cases in HUNT2 (N=52,491) and prevalent cases and baseline statin users in UKBB (N=456,702)

A. PGS_{CAD}~Sex+Age+Sex*Age in HUNT2 including prevalent cases			
Variable	Beta	SE	P-value
Intercept	0.118	0.019	3.6e-10
Age (year)	-2.0e-3	3.6e-4	5.7e-8
Sex (0=female, 1=male)	-0.035	0.028	0.210
Sex*Age (year for males compared to females)	-2.0e-4	5.3e-4	0.705
B. PGS_{CAD}~Sex+Age+Sex*Age in UKBB including prevalent cases			
Intercept	0.084	0.015	4e-8
Age (year)	-0.001	0.000	0.004
Sex (0=female, 1=male)	0.030	0.021	0.16
Sex*Age (year for males compared to females)	-0.001	0.000	0.12

PGS_{CAD}=Coronary artery disease polygenic score

Supplemental Table 8. Cox proportional hazards model statistics for the additive PGS_{CAD} model (model C1)

Variable/term (units)	Effect	SE	HR	P-value
Age ² (year ²)	-1.27e-3	9.9e-5	0.999	1.02e-37
Sex (female=0, male=1)	0.774	0.038	2.17	8.52e-93
Age (year)	0.237	0.013	1.27	2.63e-77
PGS _{CAD} (SD-units)	0.354	0.019	1.42	3.08e-80

SE=Standard error of the effect, HR=Hazard ratio, PGS_{CAD}=Coronary artery disease polygenic score, SD=Standard deviation

Supplemental Table 9. Diagnostic metrics for Pooled cohort equation and all models with the CAD polygenic score in HUNT2 dataset.

Risk model	Incident cases with risk $\geq 7.5\%$	Incident cases with risk $< 7.5\%$	Non-cases with risk $\geq 7.5\%$	Non-cases with risk $< 7.5\%$	Specificity/ Selectivity	Sensitivity/ Recall	C-index [95% confidence interval]
ASCVD risk score	2204	770	9979	38083	79.2%	74.1%	NA*
PGS _{CAD} additive model (model C1)	2290	684	11127	36935	76.8%	77.0%	0.838 [0.832; 0.844]
PGS _{CAD} with all interactions (model C2)	2333	641	11536	36526	76.0%	78.4%	0.839 [0.833; 0.845]
PGS _{CAD} additive with ASCVD (model C3)	2284	690	10866	37196	77.4%	76.8%	0.842 [0.836; 0.848]
PGS _{CAD} with interactions and ASCVD (model C4)	2371	603	11553	36509	76.0%	79.7%	0.845 [0.839; 0.851]
2. step: ASCVD then PGS _{CAD} with interactions*	2457	517	12960	35102	73.0%	82.6%	NA*

* C-index not available as the risk score is not based on a fitted model

**This is not a model but a sequential identification of high risk individuals using first ASCVD risk score and then the model with PGS_{CAD} with both interactions within individuals with low ASCVD risk.

ASCVD=Atherosclerotic cardiovascular disease risk score,

PGS_{CAD}=Coronary artery disease polygenic score

Supplemental Table 10. Model statistics for PGS_{CAD} model with all interactions (model C2)

Variable/term (units)	Effect	SE	HR	P-value
Age² (year²)	-1.4e-3	1.0e-4	0.999	4.6e-43
Sex (female=0, male=1)	2.32	0.247	10.1	7.0e-21
Age (year)	0.274	0.014	1.315	2.9e-84
PGS_{CAD} (SD-unit)	1.207	0.181	3.343	2.5e-11
Sex*Age (year for males compared to females)	-0.023	3.5e-3	0.978	1.49e-10
Sex*PGS_{CAD} (SD-units for males compared to females)	-0.423	0.219	0.655	0.054
Age*PGS_{CAD} (SD-units per year)	-0.013	2.6e-3	0.988	1.2e-6
Sex*Age*PGS_{CAD} (SD-units per year for males compared to females)	6.0e-3	3.2e-3	1.006	0.062

SE=Standard error of the effect, HR=Hazard ratio, PGS_{CAD}=Coronary artery disease polygenic score, SD=Standard deviation

Supplemental Table 11. Model statistics for additive PGS_{CAD} model with ASCVD risk score (model C3)

Variable/term (units)	Effect	SE	HR	P-value
Age ² (year ²)	-2.2e-3	1.3e-4	0.998	1.0e-61
Sex (female=0, male=1)	0.548	0.043	1.73	7.1e-38
Age (year)	0.326	0.016	1.39	1.0e-97
ASCVD (risk/100)	2.20	0.190	9.03	7.1e-31
PGS _{CAD} (SD-units)	0.347	0.019	1.42	3.9e-77

SE=Standard error of the effect, HR=Hazard ratio, PGS_{CAD}=Coronary artery disease polygenic score, ASCVD=Atherosclerotic cardiovascular disease risk score, SD=Standard deviation

Supplemental Table 12A-B. Cox proportional hazards model statistics for additive PGS_{CAD} models for males and females separately (model S1)

A. Males				
Variable/term (units)	Effect	SE	HR	P-value
Age ² (year ²)	-1.4e-3	1.3e-4	0.999	2.4e-27
Age (year)	0.241	0.016	1.272	4.2e-52
PGS _{CAD} (SD-units)	0.357	0.024	1.429	4.1e-51
B. Females				
Age ² (year ²)	-1.3e-3	1.7e-4	0.999	1.90e-14
Age (year)	0.254	0.023	1.289	2.8e-29
PGS _{CAD} (SD-units)	0.341	0.030	1.407	5.7e-30

SE=Standard error of the effect, HR=Hazard ratio, PGS_{CAD}=Coronary artery disease polygenic score, SD=Standard deviation

Supplemental Table 13A-B. Cox proportional hazards model statistics for PGS_{CAD} models with age interaction for males and females separately (model S2)

A. Males				
Variable/term (units)	Effect	SE	HR	P-value
Age² (year²)	-1.4e-3	1.3e-4	0.999	1.4e-28
Age (year)	0.251	0.016	1.285	3.9e-53
PGS_{CAD} (SD-units)	0.780	0.130	2.182	1.7e-9
Age*PGS_{CAD} (SD-units for one year)	-6.5e-3	2.0e-3	0.994	8.9e-4
B. Females				
Age² (year²)	-1.4e-3	1.8e-4	0.999	3.8e-16
Age (year)	0.275	0.024	1.317	2.7e-31
PGS_{CAD} (SD-units)	1.207	0.184	3.345	5.7e-11
Age*PGS_{CAD} (SD-units for one year)	-0.013	2.6e-3	0.988	1.9e-6

SE=Standard error of the effect, HR=Hazard ratio, PGS_{CAD}=Coronary artery disease polygenic score, SD=Standard deviation

Supplemental Table 14A-B. Model sensitivity and specificity in UK Biobank sex-stratified models.
 These numbers are from models that only use samples with full 10-year follow-up (non-cases) or that get the CAD end-point during the first 10-years of follow-up (cases).

A. Females Risk model	Incident cases with risk $\geq 7.5\%$	Incident cases with risk $< 7.5\%$	Non-cases with risk $\geq 7.5\%$	Non-cases with risk $< 7.5\%$	Specificity/Selectivity	Sensitivity/Recall	C-index [95% Confidence interval]
ASCVD	2,330	2,941	24,577	116,102	85.1%	64.2%	-
Additive PGS_{CAD} model (model S1)	1,532	4,944	10,826	158,349	94.0%	56.7%	0.728 [0.722; 0.734]
PGS_{CAD} with age-interaction (model S2)	1,523	4,953	10,763	158,412	94.0%	56.7%	0.728 [0.722; 0.734]
PGS_{CAD} with age-interaction and ASCVD (model S3)	1,393	3,878	9,025	131,654	94.0%	57.6%	0.752 [0.746; 0.758]
2 step: ASCVD then PGS_{CAD} with age-interaction **	2,624	2,647	26,844	113,835	84.0%	66.7%	-
B. Males Risk model	Incident cases with risk $\geq 7.5\%$	Incident cases with risk $< 7.5\%$	Non-cases with risk $\geq 7.5\%$	Non-cases with risk $< 7.5\%$	Specificity/Selectivity	Sensitivity/Recall	C-index [95% Confidence interval]
ASCVD	7,871	1,533	57,494	42,934	63.6%	86.0%	-
Additive PGS_{CAD} model (model S1)	7,455	3,638	44,104	72,870	72.6%	75.3%	0.704 [0.699; 0.709]
PGS_{CAD} with age-interaction (model S2)	7,653	3,440	45,909	71,065	71.8%	76.3%	0.705 [0.700; 0.709]
PGS_{CAD} with age-interaction and ASCVD (model S3)	6,363	3,041	35,191	65,237	74.1%	75.6%	0.724 [0.719; 0.729]
2 step: ASCVD then PGS_{CAD} with age-interaction **	8,076	1,328	58,951	41,477	63.0%	87.6%	-

PGS_{CAD}=Coronary artery disease polygenic score


Supplemental Table 15A-B. Cox proportional hazards model statistics for PGS_{CAD} models with age interaction and ASCVD risk score for males and females separately (model S3)

A. Males				
Variable/term (units)	Effect	SE	HR	P-value
Age² (year²)	-2.8e-3	1.8e-4	0.997	4.5e-52
Age (year)	0.374	0.021	1.454	1.2e-73
PGS_{CAD} (SD-units)	0.778	0.130	2.176	2.0e-9
Age*PGS_{CAD} (SD-units for one year)	-6.6e-3	2.0e-3	0.993	7.5e-4
ASCVD (risk/100)	2.965	0.258	19.39	1.2e-30
B. Females				
Age² (year²)	-2.8e-3	2.4e-4	0.997	4.3e-32
Age (year)	0.419	0.030	1.521	1.9e-45
PGS_{CAD} (SD-units)	1.210	0.185	3.352	5.7e-11
Age*PGS_{CAD} (SD-units for one year)	-0.013	2.6e-3	0.987	1.2e-6
ASCVD (risk/100)	3.081	0.314	21.77	1.1e-22


SE=Standard error of the effect, HR=Hazard ratio, PGS_{CAD}=Coronary artery disease polygenic score, SD=Standard deviation, ASCVD=Atherosclerotic cardiovascular disease risk score

Supplemental Figures

Supplemental Figure 1A-B. Distribution of the Coronary artery disease polygenic score (PGS_{CAD}). Panel A shows the distribution of the raw PGS_{CAD} and panel B distribution after PC-adjustment. N=Number of samples.




Supplemental Figure 2. Calibration of the ASCVD risk score/Pooled Cohort Equation in HUNT2 dataset. Panel A shows the calibration of the full risk distribution and panel B within risks < 20%. Each dot in the figure represents 5% of the predicted risk distribution.




Supplemental Figure 3. Raw PGS_{CAD} by age and sex zoomed in Y-axis

Illustration of the selection bias in the cohort baseline showing generalized additive model (GAM) curves for PGS_{CAD} by age for males and females separately overlaid hexagonal bins of sample counts in the UKBB replication dataset. Panel A is for the analysis dataset used in the Cox models and panel B when prevalent cases are included.




A.




B.




Supplemental Figure 4. The effect of threshold on the sensitivity and specificity of model S1 (Additive PGS_{CAD} model). The panel A shows sensitivity, panel B specificity and panel C the proportion of individuals in the high-risk group for males (in blue) and females (in red) separately.



Supplemental Figure 5. The effect of threshold on the sensitivity and specificity of model S2 (PGS_{CAD} with age-interaction). The panel A shows sensitivity, panel B specificity and panel C the proportion of individuals in the high-risk group for males (in blue) and females (in red) separately.




Supplemental Figure 6. The effect of threshold on the sensitivity and specificity of model S3 (PGS_{CAD} with age-interaction and ASCVD risk score). The panel A shows sensitivity, panel B specificity and panel C the proportion of individuals in the high-risk group for males (in blue) and females (in red) separately.




Supplemental Figure 7. The effect of threshold on the sensitivity and specificity of ASCVD risk score.

The panel A shows sensitivity, panel B specificity and panel C the proportion of individuals in the high-risk group for males (in blue) and females (in red) separately.



Supplemental Figure 8. Calibration of the ASCVD risk/Pooled Cohort Equation for males and females separately. The figures are restricted to show risks < 20% and the risk threshold used in the study (7.5%) has been highlighted with a dashed line. Panel A shows the calibration for females and panel B for males.



Supplemental Figure 9. Calibration of the model S3 (PGS_{CAD} with age-interaction and ASCVD risk score) for males and females separately. The figures are restricted to show risks < 20% and the risk threshold used in the study (7.5%) has been highlighted with a dashed line. Panel A shows the calibration for females and panel B for males.

